Abstracts Archive - Page 899 of 2425 - ACR Meeting Abstracts

Abstract Number: 2110 • 2019 ACR/ARP Annual Meeting
Invasive Aspergillosis in Rheumatologic Patients in Tertiary Care Hospital in Mexico
Guillermo Guaracha-Basañez¹, Carla M. Román-Montes ², María F. González-Lara ² and Alfredo Ponce-de-León ², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico city, Mexico
Background/Purpose: Fungal infections are an important cause of morbidity and mortality in patients with rheumatic diseases. Invasive aspergillosis (IA) is a fungal infection potentially fatal,…
Abstract Number: 2111 • 2019 ACR/ARP Annual Meeting
Symptomatic Coccidioidomycosis Infections in Patients on Biologic Therapies
Alexander Peck¹, Ella Starobinska ², Gilbert Ortega ¹, Travis Maestas ¹, Jaclyn Leong ¹, Phan Saligrama ¹, Jawad Bilal ¹ and Dominick Sudano ³, ¹University of Arizona College of Medicine, Tucson, AZ, ²University of Arizona College of Medicine, Tucson, AL, ³Banner University Medical Center Tucson, Tucson
Background/Purpose: Studies have shown an increased risk of coccidioidomycosis infection in immunosuppressed patients. However, relationship of coccidioidomycosis infections with different immunosuppressive medication is not well…
Abstract Number: 2112 • 2019 ACR/ARP Annual Meeting
Real Life Serious Infections in Patients with Chronic Inflammatory Arthritis on Treatment with TNF Inhibitors
Alazne Ruiz ¹, Juan Ramón De Dios ², Belen Alvarez ¹, Margarida Vasques Rocha ², Claudia Stoye ², Susana Gil ¹, Orlando Pompei Fernández ² and Jaime Calvo-Alen³, ¹Hospital Universitario Araba, Vitoria, Pais Vasco, Spain, ²Araba University Hospital, Vitoria, Pais Vasco, Spain, ³Hospital Universitario Araba, Vitoria-Gasteiz, Spain
Background/Purpose: To study frequency and associated factors for serious infections in patients with inflammatory arthritis treated with TNF inhibitorsMethods: All the medical records of the…
Abstract Number: 2113 • 2019 ACR/ARP Annual Meeting
Biological Therapy Is Associated with Faster Recovery and Lower Frequency of Switch Treatment in Patients with Chikungunya Fever
Aline Razolin ¹, Claudia Marques ¹, Laurindo Rocha Jr², Hugo Lima ³, Lays Martins ¹, Anderson Almeida ¹, Priscila Oliveira ¹, Angela Duarte ¹, Moacyr Rego ¹, Maira Pitta ⁴ and Ieda Laurindo ⁵, ¹Universidade Federal de Pernambuco, Recife, Brazil, ²Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, Brazil, ³Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, Pernambuco, Brazil, ⁴Universidade Federal de Pernambuco, Recife, Pernambuco, Brazil, ⁵BIOBADABRASIL comittee, São Paulo
Background/Purpose: Background/purpose. The first chikungunya fever outbreak in Brazil had its peak in the first half of 2016 and many patients with rheumatologic disease using…
Abstract Number: 2114 • 2019 ACR/ARP Annual Meeting
Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases
Daisuke Kobayashi¹, Sayuri Takamura ², Yoko Wada ³, Takeshi Kuroda ⁴ and Ichiei Narita ¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Japan, ³Niigata Rinko Hospital, Niigata, Niigata, Japan, ⁴Health administration office, Niigata University, Niigata, Niigata, Japan
Background/Purpose: Intensive immunosuppressive treatment is often required for patients with autoimmune diseases, and those who are thus treated have a high risk of opportunistic infections.…
Abstract Number: 2115 • 2019 ACR/ARP Annual Meeting
BK Polyomavirus Viremia and Viruria in Patients with Autoimmune Connective Tissue Diseases: Impact of Immunosuppressants
Mamatha Katikaneni¹, Madeline Davis ¹, Carolyn Smith ² and John Vanchiere ², ¹LSUHSC- Shreveport, Shreveport, LA, ²LSUHSC- Shreveport, Shreveport
Background/Purpose: The human polyomaviruses, such as the BK and JC virus, are highly prevalent in humans but appear to cause clinical disease only in immunocompromised…
Abstract Number: 2116 • 2019 ACR/ARP Annual Meeting
Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data
Lisa Lindsay¹, Ching-Yi Chuo ², Nicholas Jones ², Joshua Galanter ², Anna McGregor ² and Katie Tuckwell ², ¹Genentech Inc, SOUTH SAN FRANCISCO, CA, ²Genentech Inc, SOUTH SAN FRANCISCO
Background/Purpose: Patients with systemic lupus erythematosus (SLE), lupus nephritis (LN) and rheumatoid arthritis (RA) are at risk of serious infections (SIs) due to the impact…
Abstract Number: 2117 • 2019 ACR/ARP Annual Meeting
Impact of Tapering Targeted Therapies (bDMARDs or Jakinibs) on the Risk of Adverse Events of Special Interest in Patients with Rheumatoid Arthritis or Spondyloarthritis: A Systematic Analysis of the Literature and Meta-analysis
DOROTHEE VINSON¹, LUC MOLLET-BENHAMOU ², Yannick Degboe ³, Thao Pham ⁴, Thomas BARNETCHE ⁵, Arnaud Constantin ⁶ and Adeline Ruyssen-Witrand ⁷, ¹AP-HM CHU Marseille, Marseille, France, ²CHU Toulouse, Toulouse, France, ³University of Glasgow, Glasgow, United Kingdom, ⁴Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, ⁵CHU Bordeaux, Toulouse, France, ⁶CHU TOUOUSE, TOULOUSE, France, ⁷Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France
Background/Purpose: A previous meta-analysis1 showed that tapering of bDMARDs does not increase the risk of relapse in rheumatoid arthritis (RA) patients with remission or low…
Abstract Number: 2118 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Tocilizumab Treatment for Anti–human T Lymphotropic Virus Type I Antibody–positive Rheumatoid Arthritis
Yushiro Endo¹, Kunihiko Umekita ², Hideki Nakamura ¹, Shoichi Fukui ³, Takahisa Suzuki ⁴, Junya Miyamoto ⁵, Toshimasa Shimizu ¹, Tomohiro Koga ¹, Shin-ya Kawashiri ¹, Naoki Iwamoto ¹, Kunihiro Ichinose ¹, Mami Tamai ¹, Tomoki Origuchi ⁶, Akitomo Okada ⁷, Keita Fujikawa ⁸, Akinari Mizokami ⁸, Naoki Matsuoka ⁹, Toshiyuki Aramaki ¹⁰, Yukitaka Ueki ¹⁰, Katsumi Eguchi ¹⁰, Yumi Kariya ², Yayoi Hashiba ¹¹, Toshihiko Hidaka ¹¹, Akihiko Okayama ² and Atsushi Kawakami ¹², ¹Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, ²University of Miyazaki, Miyazaki, Japan, ³Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Nagasaki, Japan, ⁴Sasebo City General Hospital, Sasebo, Japan, ⁵Nagasaki University Hospital Clinical Research Center, Nagasaki, Japan, ⁶Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, ⁷Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁸JCHO Isahaya General Hospital Department of Rheumatology, Isahaya, Japan, ⁹Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, ¹⁰Sasebo Chuo Hospital Rheumatic and Collagen Disease Center, Sasebo, Japan, ¹¹Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan, ¹²Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki
Background/Purpose: The asymptotic individuals with the human T lymphotropic virus type I (HTLV-I) infection rarely develop adult T cell leukemia/lymphoma (ATL) or HTLV-I–associated myelopathy (HAM).…
Abstract Number: 2119 • 2019 ACR/ARP Annual Meeting
Impact of Day of Admission and Time to Diagnostic Arthrocentesis on Mortality and Other Outcomes in Septic Arthritis: A Nationwide Analysis
Gustavo Contreras¹, Ana B Arevalo ¹, Shane Murray ¹, Faris Haddadin ¹ and Yiming Luo ¹, ¹Mount Sinai St. Luke's - West/ Icahn School of Medicine, New York, NY
Background/Purpose: Multiple studies have been done assessing the “weekend effect” and outcomes for hospitalized patients 1,2,3,4, however, there is no data evaluating the outcome of…
Abstract Number: 2120 • 2019 ACR/ARP Annual Meeting
No Evidence of an Increased Risk of Serious Infections Among 3 Classes of Biologics for Psoriasis or Psoriatic Arthritis: A Retrospective Real-World Cohort Study
Xintong Li ¹, Kathleen M Andersen², Hsien-Yen Chang ³, G. Caleb Alexander ⁴ and Jeffrey Curtis ⁵, ¹Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, ⁴Johns Hopkins Bloomberg School of Public Health. Center for Drug Safety and Effectiveness, Baltimore, MD, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The real-world risk of serious infections associated with interleukin (IL) and tumor necrosis factor-alpha (TNF-α) inhibitors for patients with psoriasis (PsO) and psoriatic arthritis…
Abstract Number: 2121 • 2019 ACR/ARP Annual Meeting
Hospitalization Trends for Bacterial Septic Arthritis in the United States from 1997 to 2014
Soumyasri Kambhatla¹, Estefania Gauto-Mariotti ² and AUGUSTINE MANADAN ³, ¹John H. Stroger Hospital of Cook County, Chicago, ²Cook County Health, chicago, ³Rush University Medical Center, chicago
Background/Purpose: Bacterial septic arthritis is a serious cause of morbidity and mortality, constituting one of the true musculoskeletal emergencies. In this abstract, we describe hospitalization…
Abstract Number: 2122 • 2019 ACR/ARP Annual Meeting
Outcomes and Risk Factors in Septic Arthritis with Underlying Rheumatic Conditions
Soumyasri Kambhatla¹, Estefania Gauto-Mariotti ² and Augustine Manadan ³, ¹John H. Stroger Hospital of Cook County, Chicago, ²John H Stroger Hospital of Cook County, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Septic arthritis is known to cause significant morbidity due to joint destruction and mortality if timely and adequate treatment is not given. In this study,…
Abstract Number: 2123 • 2019 ACR/ARP Annual Meeting
Clinical Features of Prosthetic Joint Infections in Patients with Rheumatic Diseases vs Osteoarthritis
Susan Goodman¹, Milan Kapadia ², Andy Miller ², Laura Donlin ³, Michael Henry ², Linda Russell ², Mark Figgie ⁴, Allina Nocon ² and Peter Sculco ², ¹Hospital For Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, ³Hospital For Special Surgery, New York, NY, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY
Background/Purpose: Rheumatic disease (RD) patients are at increased risk for prosthetic joint infections (PJI), however, diagnosis is challenging because active RD may mimic joint infection…
Abstract Number: 2124 • 2019 ACR/ARP Annual Meeting
Screening and Follow-up of Patients with Rheumatic Diseases and Rheumatological Treatments Infected with Trypanosoma Cruzi (American Trypanosomiasis or Chagas’ Disease). Is It Possible a Reactivation?
Ariana Ringer¹, Juan Pablo Ruffino ², Nadia Cuadranti ², Ignacio Rolla ², Juan Manuel Vandale ², Carla Achilli ², Cecilia Argento ², Florencia Martinez ², Noel Cortese ², Mariano Palatnik ², Mariana Lagrutta ³, Rodolfo Leiva ⁴, Damian Aguila ⁵, Maria Jose Svetaz ⁶, Laura Cordoba ⁷, Milagros Zafra ⁸, Telma Gambander ⁸, Patricia Sciarrata ⁶, Silvina Villar ⁹, Florencia Gonzalez ⁹, Florencia Pacini ⁹, Ana Rosa Perez ⁹, Oscar Bottasso ⁹ and Marcelo Abdala ², ¹Rheumatology. Hospital Provincial del Centenario. Universidad Nacional de Rosario, Totoras, Santa Fe, Argentina, ²Rheumatology. Hospital Provincial del Centenario. Universidad Nacional de Rosario, Rosario, ³Internal Medicine. Hospital Provincial del Centenario. Universidad Nacional de Rosario, Rosario, ⁴Cardiology. Hospital Provincial del Centenario. Universidad Nacional de Rosario, Rosario, ⁵Infectology. Hospital Provincial del Centenario. Universidad Nacional de Rosario, Rosario, ⁶Central Laboratory. UNR, Rosario, ⁷Microbiology, Rosario, ⁸Microbiology. UNR, Rosario, ⁹Immunology. IDICER, CONICET, UNR, Rosario
Background/Purpose: American Trypanosomiasis or Chagas Disease (CD) is a zoonotic infection, endemic in Latin America. It is a major cause of morbidity, mortality and economic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].